Anneliese Schneider

Title: Anneliese Schneider: Innovator in Oligonucleotide Modification

Introduction

Anneliese Schneider is a prominent inventor based in Feldafing, Germany. She has made significant contributions to the field of oligonucleotide modification, holding two patents that showcase her innovative approaches to medical treatments.

Latest Patents

Her latest patents include a method for selective oligonucleotide modification. This method involves producing a modified oligonucleotide by covalently binding at least one polymer, preferably polyalkylene oxide, and/or a compound to the 5'-end or the 3'-end of the oligonucleotide via native ligation. This invention is particularly relevant for the preparation of medicaments aimed at preventing and treating various diseases, including tumors, immune disorders, cardiovascular diseases, and viral infections. Another notable patent is a pharmaceutical composition that combines a chemotherapeutic agent with a TGF-beta antisense oligonucleotide. This composition is designed to reduce the sensitivity of cancer cells to chemotherapy, enhancing treatment efficacy.

Career Highlights

Anneliese Schneider has worked with notable companies in the biotechnology sector, including Antisense Pharma GmbH and Isarna Therapeutics GmbH. Her work in these organizations has contributed to advancements in therapeutic strategies for complex diseases.

Collaborations

Throughout her career, she has collaborated with esteemed colleagues such as Karl-Hermann Schlingensiepen and Frank Jaschinski. These partnerships have further enriched her research and development efforts.

Conclusion

Anneliese Schneider's innovative work in oligonucleotide modification and her contributions to medical science highlight her as a key figure in the field. Her patents reflect a commitment to advancing therapeutic options for serious health conditions.